Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Shares Outstanding (Diluted Average) (2021 - 2024)

Historic Shares Outstanding (Diluted Average) for Abvc Biopharma (ABVC) over the last 4 years, with Q3 2024 value amounting to $12.4 million.

  • Abvc Biopharma's Shares Outstanding (Diluted Average) rose 20589.9% to $12.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $12.4 million, marking a year-over-year increase of 20589.9%. This contributed to the annual value of $3.2 million for FY2022, which is 8736.12% down from last year.
  • Abvc Biopharma's Shares Outstanding (Diluted Average) amounted to $12.4 million in Q3 2024, which was up 20589.9% from $11.3 million recorded in Q2 2024.
  • Over the past 5 years, Abvc Biopharma's Shares Outstanding (Diluted Average) peaked at $33.1 million during Q1 2023, and registered a low of $3.1 million during Q2 2022.
  • Moreover, its 4-year median value for Shares Outstanding (Diluted Average) was $11.3 million (2024), whereas its average is $14.6 million.
  • Per our database at Business Quant, Abvc Biopharma's Shares Outstanding (Diluted Average) crashed by 8788.08% in 2022 and then surged by 24216.28% in 2024.
  • Over the past 4 years, Abvc Biopharma's Shares Outstanding (Diluted Average) (Quarter) stood at $25.1 million in 2021, then tumbled by 87.36% to $3.2 million in 2022, then increased by 28.07% to $4.1 million in 2023, then skyrocketed by 205.9% to $12.4 million in 2024.
  • Its Shares Outstanding (Diluted Average) was $12.4 million in Q3 2024, compared to $11.3 million in Q2 2024 and $9.7 million in Q1 2024.